These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37648382)

  • 1. Metabolic control and incidence of hypoglycaemia, hospitalisation and complications among Saudi patients with type 2 diabetes initiating second-line therapy: an analysis of the Saudi Arabia data from the DISCOVER Observational Study programme.
    Al Rubeaan K; Banah F; Alruwaily FG; Sheshah E; Alnaqeb D; AlQahtani AM; Ewais D; Al Juhani N; Hassan AH; Youssef AM
    BMJ Open; 2023 Aug; 13(8):e063586. PubMed ID: 37648382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study.
    Rathmann W; Charbonnel B; Gomes MB; Hammar N; Khunti K; Kosiborod M; Kuss O; Shestakova MV; Watada H; Shimomura I; Tang F; Cid-Ruzafa J; Chen H; Fenici P; Surmont F; Ji L;
    Diabetes Res Clin Pract; 2020 Jul; 165():108250. PubMed ID: 32531326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study.
    Al-Rubeaan K; Banah F; Alruwaily FG; Sheshah E; Alnaqeb D; AlQahtani AM; Ewais D; Al Juhani N; Hassan AH; Youssef AM
    Curr Med Res Opin; 2023 Jan; 39(1):27-35. PubMed ID: 36342972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of fear of hypoglycemia with second-line use of insulin secretagogues or insulin and subsequent glycemic control in patients with type 2 diabetes: An analysis using data from the DISCOVER study.
    Wang JS; Chen H; Tang F; Sheu WH
    Int J Clin Pract; 2020 Jun; 74(6):e13485. PubMed ID: 32003099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attitudes and perceptions towards hypoglycaemia in patients with diabetes mellitus: A multinational cross-sectional study.
    Naser AY; Wong ICK; Whittlesea C; Alwafi H; Abuirmeileh A; Alsairafi ZK; Turkistani FM; Bokhari NS; Beykloo MY; Al-Taweel D; Almane MB; Wei L
    PLoS One; 2019; 14(10):e0222275. PubMed ID: 31647820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study.
    Kern W; Holstein A; Moenninghoff C; Kienhöfer J; Riedl M; Kulzer B
    Exp Clin Endocrinol Diabetes; 2017 Oct; 125(9):592-597. PubMed ID: 28750429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?
    Wieringa TH; de Wit M; Twisk JWR; Snoek FJ
    J Endocrinol Invest; 2018 Feb; 41(2):249-258. PubMed ID: 28803366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
    Sullivan SD; Nicholls CJ; Gupta RA; Menon AA; Wu J; Westerbacka J; Bosnyak Z; Frias JP; Bailey TS
    Diabetes Obes Metab; 2019 Sep; 21(9):2123-2132. PubMed ID: 31144445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
    Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).
    Kosiborod M; Gomes MB; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Watada H; Shimomura I; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Khunti K;
    Cardiovasc Diabetol; 2018 Nov; 17(1):150. PubMed ID: 30486889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study.
    Cariou B; Fontaine P; Eschwege E; Lièvre M; Gouet D; Huet D; Madani S; Lavigne S; Charbonnel B
    Diabetes Metab; 2015 Apr; 41(2):116-25. PubMed ID: 25465273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy.
    Schiel R; Ulbrich S; Müller UA
    Diabetes Metab; 1998 Dec; 24(6):509-14. PubMed ID: 9932217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compliance with treatment and fear of hypoglycaemia in patients with type 2 diabetes.
    Yuksel M; Bektas H
    J Clin Nurs; 2021 Jun; 30(11-12):1773-1786. PubMed ID: 33660356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece.
    Pagkalos E; Thanopoulou A; Sampanis C; Bousboulas S; Melidonis A; Tentolouris N; Alexandrides T; Migdalis I; Karamousouli E; Papanas N
    Exp Clin Endocrinol Diabetes; 2018 Jan; 126(1):53-60. PubMed ID: 28704857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care.
    Hajos TR; Pouwer F; de Grooth R; Holleman F; Twisk JW; Diamant M; Snoek FJ
    Diabet Med; 2011 Sep; 28(9):1096-102. PubMed ID: 21843305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycaemic episodes in patients with type 2 diabetes--risk factors and associations with patient-reported outcomes: The PANORAMA Study.
    Simon D; de Pablos-Velasco P; Parhofer KG; Gönder-Frederick L; Duprat Lomon I; Vandenberghe H; Eschwège E; Bradley C
    Diabetes Metab; 2015 Dec; 41(6):470-9. PubMed ID: 26455870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER.
    Takahara M; Mita T; Katakami N; Wada F; Morita N; Kidani Y; Yajima T; Shimomura I; Watada H;
    Diabetes Ther; 2022 Feb; 13(2):251-264. PubMed ID: 34962628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States).
    Ratzki-Leewing A; Black JE; Kahkoska AR; Ryan BL; Zou G; Klar N; Timcevska K; Harris SB
    Diabetes Obes Metab; 2023 Dec; 25(12):3736-3747. PubMed ID: 37700692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.